In terms of innovation, the [Indian pharmaceutical] landscape is evolving, but not at a pace that matches global leaders
In Conversation
Practice venturing into areas that make you uncomfortable; these are the assignments that give us maximum learning and personal growth. If you have the aspiration, raise…
Our focus revolves around three key aspects: API, international formulation exports, and the domestic market... targeting a compounded annual growth rate of 25 to 30 percent…
We aim to positively surprise our customers and partners with innovative approaches
It's important not to forget the significant contributions made by the pharmaceutical industry during the pandemic. The promises and commitments made by industry players and governments…
We are steadily transforming from a relatively smaller player in generics and early-phase clinical studies to a broader and more relevant Contract Research Organization for our…
While generics continue to be a core focus, there has been a strategic shift towards emphasising innovation
Leveraging this resource [the Systeme National des Donnees de Sante (SNDS)], we conduct numerous real-world studies, positioning France among the leaders in real-world evidence generation within…
Over the next three years, our focus is set on three fundamental elements to drive growth and impact: portfolio transformation, capability building, and expanding the HCP…
Our collective journey to build a leading international dermatology company in India has just begun, and I am confident that with the dedication, passion, and unwavering…
[We must] avoid placing AI at the centre and then working backwards to find a problem. Instead, we should take a problem-centric approach, identifying real-world challenges…
Our aspirations are ambitious, aiming for a three-fold increase in size over the next 8-10 years
